Premium
Varenicline safe and effective for smoking cessation in patients with schizophrenia
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30679
Subject(s) - varenicline , bupropion , smoking cessation , medicine , schizophrenia (object oriented programming) , nicotine replacement therapy , nicotine , adverse effect , placebo , psychiatry , post hoc analysis , nicotine withdrawal , anesthesia , alternative medicine , pathology
A post hoc analysis of the Evaluating Adverse Events in a Global Smoking Cessation Study (EAGLES) has found that varenicline led to significantly higher smoking‐cessation rates than placebo among individuals with schizophrenia. Other medication treatments for smoking cessation, including bupropion and nicotine‐replacement therapy, also showed benefit for the EAGLES subpopulation with schizophrenia.